Mibiton portfolio company BioConnection invests in expansion of its current production capacity with a second production line.
Pivot Park, Oss, April 8, 2019
BioConnection will invest €12 million in a second, commercial scale, manufacturing line to keep up with the growing customer demand and to ensure its future company growth.
BioConnection, Contract Manufacturing Organization (CMO), proudly announces that it will make a significant investment of €12 million in a new production line for vials in its facility in Oss. Due to the growing demand of its current customers but also due to growing market needs, BioConnection will invest in a fully automated fill and finish line coupled to a fully automated freezedryer. This combination provides significant increases in batch size as well as in total annual production capacity. BioConnection currently is inspected and approved by EMA and US-FDA. The new production line will also be built and validated according to EMA and FDA guidelines and is expected to be fully operational, including GMP certification, in the first quarter of 2021. In the meantime the company will continue to grow on the basis of its existing filling line for vials, syringes and freeze-drying. BioConnection also recently announced (March 13, 2019) the opening of new flexible GMP areas for manual fill, rental of cleanrooms and support of ATMP’s to enable an even more flexible approach for their customers.
Dr. Alexander Willemse, CEO of BioConnection: “Although BioConnection is already 13 years young, the last 3 years have been exciting when we took over our current manufacturing facility from Merck/MSD in 2016. Based on the success of our customers and the growing market demand we will now take a major step forward by adding this new production line. I am convinced that we will further dynamically grow the company while maintaining our unique approach. The enthusiasm and spirit of our team coupled to the experience of our business development, project management, operational, technical and quality people we have on board will make it a continued success. I invite all interested companies to contact Sjaak Stevense to discuss possibilities and early transfers to our new commercial scale production line. Where needed we can already start of to date with fill and finish and freeze-drying services through our current (smaller scale) FDA certified production line“
If you want to learn what we can do for your product or project, contact us or visit our (new) website.
About BioConnection B.V.
BioConnection (www.bioconnection.eu) is a Dutch contract services and manufacturing organization for the development and manufacturing of injectable (bio)pharmaceutical products. From our own EMA/FDA approved manufacturing site in Oss, the Netherlands we service our customers. Besides our own facility we have access to various partners across Europe to enable unmatched flexibility in solutions, capacity and capability. We provide tailor made solutions and customer-oriented flexibility via our CMC services: Drug Product development, Fill and Finish, freeze-drying, technology transfers, scale-up, validations and Clinical Trial Material services.
CEO Alexander Willemse at the BioConnection production facility, Pivot Park Oss, The Netherlands. (Photo: Mibiton archive).
Mibiton to support Prolira in realizing objective delirium care.
Prolira is a Utrecht-based company developing an innovative medical device to meet current medical needs. The so-called DeltaScan is the world’s first objective device to detect acute brain failure (also called delirium). The Prolira technology is based on measuring specific patterns in brain activity (orelectroencephalography, EEG). With DeltaScan, delirium can be monitored like any other vital sign. The novel medical device enables healthcare professionals to scan their patient’s brain activity and to detect delirium as soon as it develops. To accelerate the Clinical Evaluation Program, Mibiton will finance DeltaScan monitors and disposable patches to acquire batch-wise CE certification. The investment will enable international high profile medical centers to validate the DeltaScan delirium monitoring system using a large cohort of hospitalized patients. ©photo Nils van Houts
Five Mibiton investments in 2018
In 2018, Mibiton invested in the infrastructure of five innovative Life Sciences companies. (1) Photanol, investments at the R&D facilities in Amsterdam and Delfzijl, enabling the optimization of cyanobacteria strains producing a broad range of biochemicals. (2) Prolira (Utrecht), Delta scan monitors and disposable electrode patches are financed to validate delirium monitoring using a a large cohort of hospitalized patients. (3) Meatable (Leiden), to develop the first cell-based meat products, we financed a modular bioreactor system and general laboratory equipment.(4) MicroSure (Eindhoven), MicroSure Stabilizer Systems are financed, which will be used in a clinical setting at various Medical Centres, to explore potential further enhancements of the microsurgery robot.(5) CarbExplore Research (Groningen), the investment includes analytical and general lab equipment, enabling the young industrial biotech company to professionally furnish its R&D laboratory at the Zernike Innovation Center.
In 2019, we will continue to fortify the Dutch Life Sciences Infrastructure and celebrate our 25th anniversary!
Mibiton investering in het zonnetje: Specs, Compound Handling BV
In 2015 heeft Mibiton een state-of-the-art opslagfaciliteit gefinancierd, waarmee Specs Compound Handling BV, miljoenen compounds voor farmaceutische bedrijven kan beheren. Deze Mibiton faciliteit is een belangrijke groeistap en heeft ertoe geleid dat de onderneming haar martkpositie in zowel Europa als de Verenigde Staten heeft kunnen uitbouwen.